| 32014-22-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 32014-22-5
• 化学式: C7H7BrNaO3S
• 分子量: 274.09
• InChiKey: FCEDCZVYYIJSQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2904909090

文献信息

• [EN] HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES HETERO BIARYLE INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014366A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.

  该发明提供了由式I定义或其药用盐组成的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了包括式I的化合物或其药用盐以及药用载体、稀释剂或赋形剂的药物组合物，如规范中所定义。该发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予式I的化合物或其药用盐。该发明还提供了治疗患有MMP-13酶介导疾病的患者的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、牛皮癣、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了组合物，包括式I的化合物或其药用盐，以及规范中描述的另一种药用活性成分。
• Hetero biaryl derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040048863A1

  公开（公告）日：2004-03-11

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、S、T、U、V和R2如规范中所定义。本发明还提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物中给予公式I的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者中给予公式I的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、除骨关节炎和类风湿性关节炎外的其他关节炎、心力衰竭、炎症性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者中给予公式I的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了包括公式I的化合物或其药学上可接受的盐和规范中描述的另一个药学活性成分的组合物。
• HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Bunker Amy Mae

  公开号：US20090029995A1

  公开（公告）日：2009-01-29

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.

  该发明提供了由式I或其药学上可接受的盐定义的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了药物组合物和治疗疾病的方法。
• NOVEL COMPLEXES, PROCESS FOR THEIR PREPARATION, AND MEDICINAL USE OF THEM
  申请人：KURARAY CO., LTD.

  公开号：EP0270682A1

  公开（公告）日：1988-06-15

  Pullulans having active sites formed by sulfation, phosPhorylation, sulfonation or carboxylation or their pharmacologically acceptable salts, wherein one hydrogen atom of the active sites represented by formula (I), partially sub- stituted by a group represented by the general formula (II), (wherein L1 and L2 each represents amine or unidentate amine or when taken together, represent bidentate amine. and Y represents an anionic ligand) and/or two hydrogen atoms or the active sites represented by formula (III) or of two formula (IV) groups bound to the same carbon atom or adjacent carbon atoms are partially substituted by a group represented by the formula (V), (wherein L' and L2 are the name as defined above). These compounds have an onco- static activity and are useful as oncostatic agents. Process for their preparation and their medicinal use are also dis- closed

  具有通过硫化、磷化、磺化或羧化形成的活性位点或其药理学上可接受的盐的普鲁兰 类，其中式(I)所代表的活性位点的一个氢原子部分被通式(II)所代表的基团取代，(其中 L1 和 L2 各自代表胺或非同位胺，或合在一起代表双同位胺。和 Y 代表阴离子配体）和/或两个氢原子或式（III）所代表的活性位点或与同一碳原子或相邻碳原子结合的两个式（IV）基团部分被式（V）所代表的基团取代（其中 L' 和 L2 的名称如上定义）。这些化合物具有抗静电活性，可用作抗静电剂。它们的制备工艺和药用价值也已公开。
• Polybenzazole block copolymer
  申请人：SOLVAY (Société Anonyme)

  公开号：EP1657274A1

  公开（公告）日：2006-05-17

  The invention concerns a polybenzazole block copolymer suitable for solid polymer electrolyte membranes application comprising : at least one block (B1) comprising recurring units (R), more than 50 % of said recurring units comprising at least one benzimidazole group (formula 1a and 1b) and at least one sulfonic acid group (formula 2) [recurring units (R1)]; wherein E in formula 1a can be a substituted or non-substituted carbon atom or nitrogen atom, and Q in formula 1 can be a hydrogen atom or a group comprising a sulfonic acid group; and at least one block (B2) comprising recurring units (R'), more than 50 % by moles of said recurring units comprising at least one benzazole group chosen among benzothiazole group (formula 3 a and 3b) and benzoxazole group (formula 4a and 4b) [recurring units (R2)], wherein E' and E" in formula 3a and 4a, respectively, can be a substituted or non-substituted carbon atom or nitrogen atom, and the block (B2) is free from sulfonic acid groups. The invention also relates to a polybenzazole polymer composition thereof, a solid polymer electrolyte membrane therefrom, a solid polymer electrolyte doped membrane therefrom, and the fuel cell therefrom.

  本发明涉及一种适用于固体聚合物电解质膜应用的聚苯唑嵌段共聚物，包括： 至少一个嵌段（B1），该嵌段包含重复单元（R），其中 50%以上的重复单元包含至少一个苯并咪唑基团（式 1a 和 1b）和至少一个磺酸基团（式 2）[重复单元（R1）]； 其中，式 1a 中的 E 可以是取代或未取代的碳原子或氮原子，式 1 中的 Q 可以是氢原子或包含磺酸基的基团； 以及 至少一个包含递归单元（R'）的嵌段（B2），以摩尔数计，50% 以上的所述递归单元包含至少一个苯并唑基团，可从苯并噻唑基团（式 3 a 和 3b）和苯并恶唑基团（式 4a 和 4b）中选择[递归单元（R2）]、 其中，式 3a 和 4a 中的 E' 和 E "分别可以是取代或非取代的碳原子或氮原子，嵌段（B2）不含磺酸基团。 本发明还涉及一种聚苯唑聚合物组合物、由其制成的固体聚合物电解质膜、由其制成的固体聚合物电解质掺杂膜以及由其制成的燃料电池。